Epizyme, Inc. was a Cambridge, Massachusetts biopharmaceutical company developing epigenetic therapies for cancer and other diseases. Its lead product, TAZVERIK (tazemetostat), is an oral EZH2 inhibitor approved by the FDA for epithelioid sarcoma and relapsed/refractory follicular lymphoma. Epizyme was acquired by Ipsen in 2022. - View it on GitHub